WHO recommends injectable lenacapavir for HIV prevention globally
who.int —
The World Health Organization (WHO) now recommends injectable lenacapavir (LEN) as a twice-yearly pre-exposure prophylaxis (PrEP) option for HIV prevention. This marks a significant step in expanding HIV prevention choices globally. The new guidelines, announced at the 13th International AIDS Society Conference in Kigali, Rwanda, offer a long-acting alternative to daily oral pills. LEN is designed for those facing adherence challenges or stigma, with just two doses per year. The WHO also recommended simplified HIV testing to support LEN and other long-acting PrEP delivery. These actions aim to diversify HIV prevention strategies and address the 1.3 million new HIV infections in 2024.